Date: 11-May-2020

Cipla Gets EIR From US FDA For Bommasandra API Facility

Cipla has received establishment inspection report (EIR) from United States Food and Drug Administration (FDA) for API manufacturing facility in Bommasandra, Bengaluru.

The inspection was carried out between January 20, 2020 to January 24, 2020.

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions